Search

Global Health Watch: FY26 Proposed Budget Cuts, New FDA Leadership, WHO + UNAIDS and more

This week the proposed US 2026 budget was released by the White House and would slash funding across the entire federal government, gutting NIH and other agencies in the Department of Health and Human Services, and further reduce foreign assistance. In addition, a hostile critic of the US FDA is appointed to lead its Center for Biologics Evaluation and Research, which oversees vaccines amongst other things. Also, the UN is looking at significant cost-cutting, with UNAIDS looking to shed more than half its staff, along with reports of possibly folding it into WHO.

Critical Advocacy: How Civil Society is defending the HIV Response and Global Health 

In this episode of PxPulse Live, two veteran global health leaders from civil society join us to talk about how civil society is responding. Amanda Banda is Strategic Advisor to the COMPASS Coalition and Asia Russell is Executive Director of Health Gap, and both are members of CHANGE, a coalition with more than 1,500 people, from organizations in nearly every continent, working in coordination to defend global health and the HIV response.

Worldwide Prevention, Shared Protection

This Issue Brief describes the impacts of the elimination and reduction of funding that supports sexually transmitted infection (STI) research, testing, and prevention programming. This funding is critically important as STI rates continue to increase globally with more than 1 million curable STIs, including chlamydia, gonorrhea, syphilis, and trichomoniasis, acquired every day. Without appropriate testing, treatment, and prevention programs, there is a risk that STI rates will continue to increase leading to more cases of infertility, pelvic inflammatory disease, and cancers.

Worldwide Prevention, Shared Protection

Underserved, Underfunded, and Unseen: The Realities of HIV/STI Prevention

Modelling Shows the Potential of LA-PrEP

Modelling data from South Africa demonstrate the potential of injectable PrEP to dramatically reduce HIV incidence by up to 90% by 2044, and potentially even sooner with more aggressive uptake. This potential goes beyond South Africa, lighting the way toward epidemic control the world over.

PrEP Delivery Imperiled

Programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health. This graphic illustrates some of the severe measurable impacts of these cuts.

PxWire Volume 15, Issue 2

The field of HIV prevention is confronted with two opposing forces—programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health while next-generation long-acting products have never held greater promise to accelerate HIV prevention and help the world achieve epidemic control. This issue provides a snapshot on threats to delivering PrEP, the potential of injectable lenacapavir (LEN) for PrEP, and on the implications of upstream research and development of other long-acting PrEP.

An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible

The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.

Science in the Crosshairs: Research Advocacy in a Time of Crisis